Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of iparomlimab + tuvonralimab + platinum chemotherapy + anlotinib in SMARCA4-deficient advanced non-small cell lung cancer
ChiCTR2500102932Phase 4Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- May 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab, tuvonralimab and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Shandong First Medical University. Primary endpoint: progression-free survival. Planned start May 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500102932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102932.